HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2:CEP17 ratio?

• Published in: Pathology Vol. 46; no. 3; pp. 184 - 187
• Main Authors: Kumarasinghe, Marian Priyanthi, de Boer, Willem Bastiaan, Khor, Tze Sheng, Ooi, Esther M., Jene, Nic, Jayasinghe, Sureshini, Fox, Stephen B.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.04.2014
• Subjects: Adenocarcinoma - genetics; Adenocarcinoma - pathology; Amplification; Centromere - genetics; Chromosomes, Human, Pair 17 - genetics; copy number; double probe method; Esophageal Neoplasms - genetics; Esophageal Neoplasms - pathology; Esophagogastric Junction; gastric/gastro-esophageal junctional carcinoma; Gene Amplification; Gene Dosage; HER2 status; Humans; Immunohistochemistry; In Situ Hybridization; Neoplasm Grading; ratio; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; single probe method; Stomach Neoplasms - genetics; Stomach Neoplasms - pathology; Amplification; single probe method; double probe method; copy number; HER2 status; gastric/gastro-esophageal junctional carcinoma; ratio

The aim of this study was to compare HER2 amplification, as determined by the HER2 copy number (CN) and the HER2/ CEP17 ratio, with protein expression in gastric and gastro-oesophageal junction (G/GOJ) adenocarcinoma. HER2 immunohistochemistry (IHC) and silver in situ hybridisation (SISH) were perfo...